Lantern Pharma Inc. (LTRN)

Lantern Pharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	7.51	21.94	37.2	51.52	19.23
Short-Term Investments	16.5	19.36	17.99	19.2	-
Cash & Short-Term Investments	24.01	41.3	55.2	70.73	19.23
Cash Growth	-41.86%	-25.17%	-21.96%	267.80%	1460.78%
Other Receivables	0.1	0.86	0.59	0.18	-
Receivables	0.1	0.86	0.59	0.18	-
Prepaid Expenses	1.14	1.18	0.76	1.03	0.82
Restricted Cash	-	-	0.54	-	-
Other Current Assets	-	-	1.63	0.78	0.19
Total Current Assets	25.25	43.34	58.72	72.72	20.24
Property, Plant & Equipment	0.29	0.28	0.1	0.22	0.02
Long-Term Deferred Charges	-	-	-	-	0.1
Other Long-Term Assets	0.04	0.03	0.02	1.02	-
Total Assets	25.57	43.65	58.84	73.95	20.36
Accounts Payable	2.42	0.94	0.93	0.68	0.43
Current Portion of Leases	0.19	0.17	0.05	0.15	-
Other Current Liabilities	1.73	1.56	1.81	1.49	0.12
Total Current Liabilities	4.33	2.68	2.8	2.33	0.55
Long-Term Debt	-	-	-	-	0.11
Long-Term Leases	0.05	0.06	-	0.05	-
Total Liabilities	4.38	2.74	2.8	2.38	0.66
Common Stock	0	0	0	0	0
Additional Paid-In Capital	97.06	96.26	95.69	96.69	32.36
Retained Earnings	-76.03	-55.24	-39.28	-25.02	-12.66
Comprehensive Income & Other	0.15	-0.11	-0.37	-0.09	-
Total Common Equity	21.19	40.91	56.04	71.57	19.7
Shareholders' Equity	21.19	40.91	56.04	71.57	19.7
Total Liabilities & Equity	25.57	43.65	58.84	73.95	20.36
Total Debt	0.24	0.23	0.05	0.2	0.11
Net Cash (Debt)	23.77	41.07	55.14	70.52	19.12
Net Cash Growth	-42.12%	-25.52%	-21.80%	268.82%	1451.97%
Net Cash Per Share	2.21	3.79	5.08	6.47	4.44
Filing Date Shares Outstanding	10.78	10.74	10.86	10.78	11.17
Total Common Shares Outstanding	10.78	10.72	10.86	11.09	6.22
Working Capital	20.92	40.66	55.92	70.39	19.68
Book Value Per Share	1.96	3.82	5.16	6.45	3.17
Tangible Book Value	21.19	40.91	56.04	71.57	19.7
Tangible Book Value Per Share	1.96	3.82	5.16	6.45	3.17

Updated Nov 7, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q